Seaport Therapeutics reported strong clinical progress and financial momentum in its first quarter 2026 results, with multiple advances across its neuropsychiatry pipeline. The company’s GlyphAllo (SPT-300) program for major depressive disorder is advancing in its Phase 2b BUOY-1 trial with enrollment on track for a full prespecified target of approximately 360 patients, with topline data expected in the first half of 2027. A Phase 1 driving simulation trial evaluating the potential impact of GlyphAllo on simulated driving performance in healthy volunteers is also underway, with results expected in the second half of 2026.
The company’s Phase 1 and Phase 2a data for GlyphAllo were published in Science Translational Medicine, detailing safety and tolerability following single- and multiple-ascending oral doses ranging from 70–1000 mg, dose-dependent therapeutic plasma exposures of allopregnanolone, and pharmacodynamic effects in the brain including potent blunting of the acute physiological stress response in a validated clinical model of anxiety.
On the financial front, R&D expenses increased to $21.4 million for Q1 2026 from $10.5 million in Q1 2025, primarily due to increased clinical development expenses as both GlyphAllo and GlyphAgo advanced into later-stage development and related personnel costs. Cash, cash equivalents, and investments totaled $212.6 million as of March 31, 2026. Subsequent to quarter-end, Seaport closed an upsized IPO raising gross proceeds of $260.0 million. The company expects its current cash position to support operating plans into 2029, covering multiple anticipated topline data readouts.
The company appointed Sharon Mates, Ph.D., former co-founder and CEO of Intra-Cellular Therapies (acquired by Johnson & Johnson for $14.6 billion in 2025), to its board of directors. Seaport also received an ARPA-H award of up to $15 million with Monash Institute of Pharmaceutical Sciences supporting development of GlyphCele, an oral prodrug addressing gut lymphatics dysfunction linked to metabolic disease and pancreatic cancer.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.rutlandherald.com/news/business/seaport-therapeutics-reports-first-quarter-2026-financial-results-and-highlights-recent-corporate-and-clinical-progress/article_51878c45-da83-5946-8c98-a4630103d938.html